ArticleHepatology international2025

The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan.

Shigeo Shimose et al.PubMed ↗Publisher ↗

No numbers read from the abstract.